Glycerin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Glycerin: From Multi-Use Consumer and OTC Products to Cauda Equina Syndrome
One-Sentence Summary
Glycerin is a widely used ingredient in US-marketed products, including rectal suppositories, eye drops, a moisturizing cream and a soap. The TxGNN model predicts it may be effective for cauda equina syndrome, but no clinical trials and no publications were retrieved for this pairing. The prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the available regulatory data (products include suppository, eye drop, cream and soap forms) |
| Predicted New Indication | Cauda equina syndrome |
| TxGNN Prediction Score | 99.60% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Glycerin is a small polyol used as an osmotic agent, lubricant and moisturizer across many product types. Its efficacy in those settings is established, but no data here connect that action to cauda equina syndrome, a compressive injury to the lumbosacral nerve roots.
The retrieved data give no plausible pharmacological rationale for this prediction. The high TxGNN score (99.60%, rank 10,093) most likely reflects patterns in the knowledge graph rather than a demonstrated biological link. It should be treated as a hypothesis-generating signal only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| M006 | CLENZIDERM THERAPEUTIC MOISTURIZER | Cream | Obagi Cosmeceuticals LLC |
| M018 | Clear Eyes Nighttime | Solution/Drops | Prestige Brands Holdings, Inc. |
| M016 | ANTIBACTERIAL FRUITY ZEST | Soap | Quimicas Handal de Centroamerica SA de CV |
| M007 | Stratuscare Adult Glycerin | Suppository | Stratus Pharmaceuticals |
| M007 | Glycerin | Suppository | Amerisource Bergen/Good Neighbor Pharmacy |
Approved indication text is not listed for these authorizations. Only 5 of the 20 authorizations are shown.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for cauda equina syndrome has no supporting trials, no literature and no identifiable mechanism. It is Level L5 (model prediction only), so it does not justify further investment at this time.
Two other predicted indications for glycerin have more support. Open-angle glaucoma (score 99.59%) and irritable bowel syndrome (score 99.49%) are both Level L4, with plausible osmotic-agent and laxative rationales. Neither has direct evidence of efficacy. They are better candidates for follow-up research questions than cauda equina syndrome.
To proceed, the following is needed:
- Mechanism of action data for glycerin (DrugBank)
- Package insert warnings and contraindications from the FDA website
- A literature and trial search targeted specifically at glycerin in cauda equina syndrome, to confirm the evidence gap
- Approved indication text for the main US authorizations, to establish the original indication
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.